fbpx

SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!
+1 786 238 2170

Global Stem Cells GroupGlobal Stem Cells Group

  • Home
  • Our Story
  • Advisory Board
  • Investors
  • Companies
  • Press Releases
  • Blog
CONTACT
  • Home
  • Corporate News / Blog
  • How does the U.S. FDA regulate cell therapies?
March 22, 2023

How does the U.S. FDA regulate cell therapies?

Tuesday, 27 February 2018 / Published in Corporate News / Blog

How does the U.S. FDA regulate cell therapies?

How does the U.S. FDA regulate cell therapies? (351 vs 361 Products)
In the United States, cellular therapies are regulated by the FDA’s Office of Cellular, Tissue, and Gene Therapies (OCTGT) within the FDA Center for Biologics Evaluation and Research (CBER).
According to the FDA, the Center for Biologics Evaluation and Research (CBER) regulates:

Cellular therapy products
Human gene therapy products
Certain devices related to cell and gene therapy
CBER uses both the Public Health Service Act and the Federal Food Drug and Cosmetic Act as enabling statutes for oversight.
In the U.S., human tissues intended for transplantation are regulated by the FDA as “Human cells, tissues and cellular and tissue-based products” or “HCT/Ps.” Under U.S. law, any company that engages in the collection, processing, storage, screening/testing, packaging, or distribution of HCT/Ps must register with the FDA.
351 vs. 361 Products
Currently, the FDA’s Center for Biologics Evaluation and Research (CBER) is responsible for regulating HCT/Ps and it has two different paths for cell therapies that it constructed to reflect what it considers to be “relative risk”. These pathways are commonly called “361” and “351” products.
Cell therapies can potentially be regulated under either pathway, as described below:
361 Products
361 products that meet all the criteria outlined in 21 CFR 1271.10(a) are regulated as HCT/Ps and are not required to be licensed or approved by the FDA. These products are called “361 products,” because they are regulated under Section 361 of the Public Health Service (PHS) Act.
351 Products
In contrast, if a cell therapy product does not meet all the criteria outlined in 21 CFR 1271.10(a)), then it is regulated as a “drug, device, or biological product” under the Federal Food, Drug, and Cosmetic Act (FDCA) and Section 351 of the PHS Act. These 351 products require clinical trials to demonstrate safety and efficacy in a process that is nearly identical to that what is required for pharmaceutical products to enter the marketplace.

What you can read next

The different types of stem cells and their current uses
Using Bone Marrow Stem Cells to Treat Heart Disease
A Good Night’s Sleep Protects Stem Cells From Premature Aging

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Send Us a Message

  • Home
  • Our Story
  • Advisory Board
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2022 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA and endorsed by the Universidad Autónoma del BENI: UAB and by the Atlantic International University

  • Home
  • Our Story
  • Advisory Board
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2022 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA and endorsed by the Universidad Autónoma del BENI: UAB and by the Atlantic International University

TOP